Who are Liposome doxorubicin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cipro, Amekrin, Doxorubicin Hydrochloride, Doxorubicin hydrochloride liposome, aclacinomycin, Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liposome-doxorubicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Liposome doxorubicin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liposome doxorubicin (Liposome doxorubicin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Liposomal chemotherapy; topoisomerase II inhibitor. Area: Oncology.

marketed Liposomal chemotherapy; topoisomerase II inhibitor DNA topoisomerase II Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Liposome doxorubicin (Liposome doxorubicin) — Sun Yat-sen University. Liposome-encapsulated doxorubicin delivers the chemotherapy agent doxorubicin to cancer cells while reducing exposure to healthy tissues, thereby improving tolerability.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Liposome doxorubicin TARGET	Liposome doxorubicin	Sun Yat-sen University	marketed	Liposomal chemotherapy; topoisomerase II inhibitor	DNA topoisomerase II
Cipro	ciprofloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Amekrin	AMSACRINE		marketed	amsacrine	DNA topoisomerase 2-beta, Solute carrier family 22 member 1, DNA topoisomerase II	1987-01-01
Doxorubicin Hydrochloride	Doxorubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA topoisomerase II, nucleotide bases
Doxorubicin hydrochloride liposome	Doxorubicin hydrochloride liposome	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	marketed	Anthracycline chemotherapy agent (liposomal formulation)	DNA topoisomerase II
aclacinomycin	aclacinomycin	Chinese PLA General Hospital	phase 3		72 kDa type IV collagenase, DNA topoisomerase II, 5-hydroxytryptamine receptor 2B
Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone	Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone	Technische Universität Dresden	marketed	Combination chemotherapy (nucleoside analog + topoisomerase II inhibitors)	DNA polymerase (cytarabine); Topoisomerase II (amsacrine, mitoxantrone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-04-21 — Cipro · 11369566 · Formulation · US
2029-04-21 — Cipro · 9603796 · Compound · US
2029-04-21 — Cipro · 9205048 · Method of Use · US
2029-12-11 — Cipro · 9233068 · Formulation · US
2030-04-27 — Cipro · 8318817 · Method of Use · US
2035-07-01 — Cipro · 9220796 · Formulation · US
2037-11-12 — Cipro · 11040004 · Method of Use · US
2038-11-27 — Cipro · 11246863 · Formulation · US

Sponsor landscape (Liposomal chemotherapy; topoisomerase II inhibitor class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Liposome doxorubicin — Competitive Intelligence Brief. https://druglandscape.com/ci/liposome-doxorubicin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab